



## **2025 Formulary Changes**

**EFFECTIVE DATE: 09/01/2025**

**AFFECTED DRUG NAME / ALTERNATIVE DRUG(S) AND TIER(S)**

<b>Drug Name</b>	<b>Alternate Drugs and Tier</b>	<b>Change Type</b>	<b>Change Reason</b>
PROMACTA 75 MG ORAL TABLET	ELTROMBOPAG OLAMINE 75 MG ORAL TABLET-5	BRAND DELETION, ADD FRF GENERIC	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT
PROMACTA 50 MG ORAL TABLET	ELTROMBOPAG OLAMINE 50 MG ORAL TABLET-5	BRAND DELETION, ADD FRF GENERIC	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT
PROMACTA 12.5 MG ORAL TABLET	ELTROMBOPAG OLAMINE 12.5 MG ORAL TABLET-5	BRAND DELETION, ADD FRF GENERIC	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT
PROMACTA 25 MG ORAL POWD PACK	ELTROMBOPAG OLAMINE 25 MG ORAL POWD PACK-5	BRAND DELETION, ADD FRF GENERIC	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT
PROMACTA 12.5 MG ORAL POWD PACK	ELTROMBOPAG OLAMINE 12.5 MG ORAL POWD PACK-5	BRAND DELETION, ADD FRF GENERIC	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT
COMPLERA 200-25-300 ORAL TABLET	EMTRICITABINE-RILPIVIRNE-TENOF 200-25-300 ORAL TABLET-5	BRAND DELETION, ADD FRF GENERIC	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT
PROMACTA 25 MG ORAL TABLET	ELTROMBOPAG OLAMINE 25 MG ORAL TABLET-5	BRAND DELETION, ADD FRF GENERIC	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT

**EFFECTIVE DATE: 08/01/2025**

**AFFECTED DRUG NAME / ALTERNATIVE DRUG(S) AND TIER(S)**

<b>Drug Name</b>	<b>Alternate Drugs and Tier</b>	<b>Change Type</b>	<b>Change Reason</b>
APTOM 600 MG ORAL TABLET	ESLICARBAZEPINE ACETATE 600 MG ORAL TABLET-5	BRAND DELETION, ADD FRF GENERIC	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT
APTOM 400 MG ORAL TABLET	ESLICARBAZEPINE ACETATE 400 MG ORAL TABLET-5	BRAND DELETION, ADD FRF GENERIC	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT
APTOM 800 MG ORAL TABLET	ESLICARBAZEPINE ACETATE 800 MG ORAL TABLET-5	BRAND DELETION, ADD FRF GENERIC	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT
JYNARQUE 30 MG- 15MG ORAL TABLET SEQ	TOLVAPTAN 30 MG-15MG ORAL TABLET SEQ-5	BRAND DELETION, ADD FRF GENERIC	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT
JYNARQUE 90 MG- 30MG ORAL TABLET SEQ	TOLVAPTAN 90 MG-30MG ORAL TABLET SEQ-5	BRAND DELETION, ADD FRF GENERIC	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT
JYNARQUE 60 MG- 30MG ORAL TABLET SEQ	TOLVAPTAN 60 MG-30MG ORAL TABLET SEQ-5	BRAND DELETION, ADD FRF GENERIC	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT
JYNARQUE 15 MG- 15MG ORAL TABLET SEQ	TOLVAPTAN 15 MG-15MG ORAL TABLET SEQ-5	BRAND DELETION, ADD FRF GENERIC	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT
JYNARQUE 45 MG- 15MG ORAL TABLET SEQ	TOLVAPTAN 45 MG-15MG ORAL TABLET SEQ-5	BRAND DELETION, ADD FRF GENERIC	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT
APTOM 200 MG ORAL TABLET	ESLICARBAZEPINE ACETATE 200 MG ORAL TABLET-5	BRAND DELETION, ADD FRF GENERIC	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT

**EFFECTIVE DATE: 06/01/2025**

**AFFECTED DRUG NAME / ALTERNATIVE DRUG(S) AND TIER(S)**

<b>Drug Name</b>	<b>Alternate Drugs and Tier</b>	<b>Change Type</b>	<b>Change Reason</b>
PURIXAN 20 MG/ML ORAL ORAL SUSP	MERCAPTOPURINE 20 MG/ML ORAL ORAL SUSP-5	BRAND DELETION, ADD FRF GENERIC	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT

**EFFECTIVE DATE: 04/01/2025**

**AFFECTED DRUG NAME / ALTERNATIVE DRUG(S) AND TIER(S)**

<b>Drug Name</b>	<b>Alternate Drugs and Tier</b>	<b>Change Type</b>	<b>Change Reason</b>
TRUSELTIQ 75 MG/DAY ORAL CAPSULE		DELETION OF DRUG FROM FORMULARY	NO LONGER FDA APPROVED
TRUSELTIQ 50 MG/DAY ORAL CAPSULE		DELETION OF DRUG FROM FORMULARY	NO LONGER FDA APPROVED
TRUSELTIQ 100 MG/DAY ORAL CAPSULE		DELETION OF DRUG FROM FORMULARY	NO LONGER FDA APPROVED
MESNEX 400 MG ORAL TABLET	MESNA 400 MG ORAL TABLET-5	BRAND DELETION, ADD FRF GENERIC	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT
TRUSELTIQ 125 MG/DAY ORAL CAPSULE		DELETION OF DRUG FROM FORMULARY	NO LONGER FDA APPROVED

**EFFECTIVE DATE: 02/01/2025**

**AFFECTED DRUG NAME / ALTERNATIVE DRUG(S) AND TIER(S)**

<b>Drug Name</b>	<b>Alternate Drugs and Tier</b>
SPRYCEL 70 MG ORAL TABLET	DASATINIB 70 MG ORAL TABLET-5
SPRYCEL 80 MG ORAL TABLET	DASATINIB 80 MG ORAL TABLET-5
SPRYCEL 140 MG ORAL TABLET	DASATINIB 140 MG ORAL TABLET-5
SPRYCEL 20 MG ORAL TABLET	DASATINIB 20 MG ORAL TABLET-5
SPRYCEL 50 MG ORAL TABLET	DASATINIB 50 MG ORAL TABLET-5
SPRYCEL 100 MG ORAL TABLET	DASATINIB 100 MG ORAL TABLET-5

**CHANGE TYPE**

**BRAND DELETION, ADD FRF GENERIC**

**CHANGE REASON**

**REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT**